SherifMostafaEl-HaraziMD

Ophthalmology • Glendale, CA

Retinal Disease

Physician

Join to view full profile

Dr. El-Harazi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. El-Harazi's full profile

Already have an account?

Office
1510 S Central Ave
Suite 300
Glendale, CA 91204
Phone+1 818-265-2255

Fax+1 818-507-5027

Education & Training

University of Texas Health Science Center at HoustonResidency, Ophthalmology, 1997 - 2001
University of Texas Health Science Center at HoustonInternship, Transitional Year, 1996 - 1997
University of Alexandria Faculty of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 2001 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Medflow EHR, Medflow, Inc., 2013

Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain Start of enrollment: 2016 Jun 01
Completed
Phase 3
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease Start of enrollment: 2016 Jun 01
Completed
Phase 3

Publications & Presentations

PubMed

Sepetaprost 0.002% Non-Inferiority Versus Timolol 0.5% in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: ANGEL-2.
David L Wirta, Sherif M El-Harazi, Michael E Tepedino, Jason Bacharach
Ophthalmology. Glaucoma. 2025-03-03
Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.
David Wirta, William Lipsky, Melissa Toyos, Joseph Martel, John Goosey
BMC Ophthalmology. 2024-07-17
9 citations
Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The Virgo Phase 3, Randomized, Double-Masked, Controlled Study.
Shane Kannarr, Sherif M El-Harazi, Majid Moshirfar, Christopher Lievens, Jennifer Lee Kim
American Journal of Ophthalmology. 2023-09-01

Press Mentions

Efficacy of Verkazia to Treat Rare Eye Infection (Vernal Keratoconjunctivitis)May 12th, 2022
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United StatesMay 2nd, 2022